Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan

摘要

Provided are methods for treating pancreatic cancer in a patient by administering liposomal irinotecan (MM-398) alone or in combination with additional therapeutic agents. In one embodiment, the liposomal irinotecan (MM-398) is co-administered with 5-fluorouracil and leucovorin.

主权项

1. A method of treating metastatic adenocarcinoma of the pancreas in a human patient who has previously been treated with the antineoplastic agent gemcitabine, the method comprising intravenously administering to the patient once every two weeks 80 mg/m2 of the antineoplastic agent MM-398 liposomal irinotecan in combination with 200 mg/m2 of (l)-form of leucovorin or 400 mg/m2 of the (l+d) racemic form of leucovorin and 2,400 mg/m2 of the antineoplastic agent 5-fluorouracil to treat the metastatic adenocarcinoma of the pancreas in the human patient, where no other antineoplastic agent is administered to the human patient for treatment of the metastatic adenocarcinoma of the pancreas.